GSA Global Quality Measures Survey Closes March 1st, 2019
The GSA Global Quality Measures Survey closes March 1st, 2019.
Please participate and encourage your colleagues and institutions, if you haven’t yet.
The survey is available in English, Chinese, Spanish, Portuguese, and German.
Despite a recent resolution by the WHO and increasing worldwide recognition that sepsis poses a major global health threat, our knowledge of what sepsis surveillance, treatment, quality improvement (QI), and reporting practices look like across the world is surprisingly limited and fragmented. As a community of stakeholders from policy makers to healthcare providers, we need to know more about how these programs and practices vary between regions, between patient populations, and between healthcare settings.
The GSA is conducting a global survey, which will operate through 2 arms.
The first arm is a targeted survey that will be distributed to the head of every national government health agency in the UN member states. The second arm is a publicly available survey that is targeted to various healthcare providers, health administrators, and government health officials across the world. We aim for participation that includes every UN member state, from diverse types of healthcare providers, and from diverse patient populations.
The survey begins by clarifying respondents’ roles to ask only the questions that are relevant to them. The following 15-20 questions should take about 7-9 minutes to complete. All responses are anonymous, and no data will ever be released in a manner that would allow any specific healthcare institution to be singled out.
Purpose of the Survey
To characterize the current practices related to sepsis surveillance, treatment, quality improvement, and reporting worldwide.
Date Protection and Privacy
All data is s collected through REDCap, a fully encrypted and secure data abstraction platform that has become a global industry standard to maintain both security and privacy for protected health information (PHI) and personally identifiable information (PII) in clinical trials and human subjects research.
This survey does not ask any questions that constitute PHI. The risk of any responses being able to identify individuals or institutions is extremely minimal. Nevertheless, all data is fully encrypted and housed in a secure location. One only individual will directly access raw data for analysis, and all data reports will always presented in aggregate only.
Share the Survey
Please share the survey with your colleagues and other interested parties: